Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (Q37409862)

20 August 2017

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (English)

1 reference

20 August 2017

15

Laurence Albiges

1 reference

20 August 2017

3

Bernard Escudier

1 reference

20 August 2017

24

Mario Sznol

1 reference

20 August 2017

1

Toni K Choueiri

1 reference

20 August 2017

5

Charles G Drake

1 reference

20 August 2017

Mayer N Fishman

2

1 reference

20 August 2017

David F McDermott

4

1 reference

20 August 2017

Harriet Kluger

6

1 reference

20 August 2017

Walter M Stadler

7

1 reference

20 August 2017

Jose Luis Perez-Gracia

8

1 reference

20 August 2017

Douglas G McNeel

9

1 reference

20 August 2017

Brendan Curti

10

1 reference

20 August 2017

Michael R Harrison

11

1 reference

20 August 2017

Elizabeth R Plimack

12

1 reference

20 August 2017

Leonard Appleman

13

1 reference

20 August 2017

Lawrence Fong

14

1 reference

20 August 2017

Lewis Cohen

16

1 reference

20 August 2017

Tina C Young

17

1 reference

20 August 2017

Scott D Chasalow

18

1 reference

20 August 2017

Petra Ross-Macdonald

19

1 reference

20 August 2017

Shivani Srivastava

20

1 reference

20 August 2017

Maria Jure-Kunkel

21

1 reference

20 August 2017

John F Kurland

22

1 reference

20 August 2017

Jason S Simon

23

1 reference

20 August 2017

language of work or name

English

0 references

publication date

11 May 2016

1 reference

20 August 2017

Clinical Cancer Research

1 reference

20 August 2017

22

1 reference

20 August 2017

22

1 reference

20 August 2017

5461-5471

1 reference

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

PD-1 blockade in renal cell carcinoma: to equilibrium and beyond

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

PD-1 blockade induces responses by inhibiting adaptive immune resistance

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Innate and adaptive immune cells in the tumor microenvironment

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Chemotherapy in metastatic renal cell carcinoma today? A systematic review

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

The blockade of immune checkpoints in cancer immunotherapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Circulating biomarkers in advanced renal cell carcinoma: clinical applications

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Summaries of Affymetrix GeneChip probe level data

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1-type immune response

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

An immune-active tumor microenvironment favors clinical response to ipilimumab

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5106340

Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils

2 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27169994

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27169994

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Immune cells in the melanoma microenvironment hold information for prediction of the risk of recurrence and response to treatment

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27169994

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1158/1078-0432.CCR-15-2839

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

27169994

1 reference